ALX Oncology Holdings Azioni (NASDAQ: ALXO)

Ultime notizie per ALX Oncology Holdings (NASDAQ:ALXO) Azioni

ALX Oncology Holdings

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

ALX Oncology Holdings Inc. - Common Stock

ALX Oncology Holdings Inc

News

Guidance

FOLD

Amicus Therapeutics Raises 2024 Total Revenue Growth Guidance From 26% - 31% To 30% - 32% At CER

HC Wainwright &amp; Co. analyst Robert Burns reiterates Macrogenics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGNX#NASDAQ">MGNX</a>) with a Neutral and maintains $4 price target.

Price Target

Reiteration

Analyst Ratings

MGNX

HC Wainwright & Co. Reiterates Neutral on Macrogenics, Maintains $4 Price Target

WW International Reiterates FY24 Outlook: Sees Revenue Of At Least $770.0M Vs. $775.46M Estimate

Ionis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IONS#NASDAQ">IONS</a>) reported quarterly losses of $(0.72) per share which beat the analyst consensus estimate of $(1.16) by 37.93 percent. The company reported quarterly sales of $134.00 million which beat the analyst consensus estimate of $130.13 million by 2.97 percent. This is a 6.94 percent decrease over sales of $144.00 million the same period last year.

Earnings

IONS

Ionis Pharmaceuticals Q3 2024 Adj EPS $(0.72) Beats $(1.16) Estimate, Sales $134.00M Beat $130.13M Estimate

Morgan Stanley analyst Hamza Fodderwala maintains Qualys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QLYS#NASDAQ">QLYS</a>) with a Underweight and raises the price target from $123 to $126.

QLYS

Morgan Stanley Maintains Underweight on Qualys, Raises Price Target to $126

Royalty Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPRX#NASDAQ">RPRX</a>) reported quarterly earnings of $1.04 per share which beat the analyst consensus estimate of $0.93 by 11.83 percent. The company reported quarterly sales of $565.00 million which missed the analyst consensus estimate of $696.10 million by 18.83 percent. This is a 5.41 percent increase over sales of $536.00 million the same period last year.

Earnings Beats

RPRX

Royalty Pharma Q3 2024 Adj EPS $1.04 Beats $0.93 Estimate

Morgan Stanley analyst Michael Cyprys downgrades Cboe Global Markets (BATS:<a class="ticker" href="https://www.benzinga.com/stock/CBOE#BATS">CBOE</a>) from Equal-Weight to Underweight and announces $199 price target.

Downgrades

CBOE

Morgan Stanley Downgrades Cboe Global Markets to Underweight, Announces $199 Price Target

JP Morgan analyst Samik Chatterjee downgrades Super Micro Computer (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) from Neutral to Underweight and lowers the price target from $50 to $23.

SMCI

JP Morgan Downgrades Super Micro Computer to Underweight, Lowers Price Target to $23

Surmodics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRDX#NASDAQ">SRDX</a>) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.29) by 55.17 percent. This is a 124.53 percent decrease over earnings of $0.53 per share from the same period last year. The company reported quarterly sales of $33.23 million which beat the analyst consensus estimate of $30.40 million by 9.32 percent. This is a 18.80 percent increase over sales of $27.97 million the same period last year.

SRDX

Surmodics Q4 2024 Adj EPS $(0.13) Beats $(0.29) Estimate, Sales $33.23M Beat $30.40M Estimate

Royalty Pharma Raises Full Year 2024 Guidance For Portfolio Receipts From $2.70B - $2.775B To $2.75B - $2.80B

WIIM

CELH

Celsius Holdings shares are trading lower after the company reported worse-than-expected Q3 financial results.

Charles River Laboratories Raises FY24 Outlook: Sees Adjusted EPS Of $10.10–$10.30 Vs. $10 Estimate (Prior View: $9.90–$10.20)

ODP shares are trading lower after the company reported worse-than-expected Q3 financial results and lowered FY24 outlook.

2024 Guidance
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="3" rowspan="1">Q4 2024 Guidance</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="3" rowspan="1">FY 2024 Guidance</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">Low</td>
<td colspan="1" rowspan="1">Baseline</td>
<td colspan="1" rowspan="1">High</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">Low</td>
<td colspan="1" rowspan="1">Baseline</td>
<td colspan="1" rowspan="1">High</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Revenue</td>
<td colspan="1" rowspan="1">$1.850B</td>
<td colspan="1" rowspan="1">$1.870B</td>
<td colspan="1" rowspan="1">$1.890B</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$7.390B</td>
<td colspan="1" rowspan="1">$7.410B</td>
<td colspan="1" rowspan="1">$7.430B</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adj. EBITDA&#x2A;1</td>
<td colspan="1" rowspan="1">$478M</td>
<td colspan="1" rowspan="1">$488M</td>
<td colspan="1" rowspan="1">$498M</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$1.885B</td>
<td colspan="1" rowspan="1">$1.895B</td>
<td colspan="1" rowspan="1">$1.905B</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adj. EBITDA Margin&#x2A;1</td>
<td colspan="1" rowspan="1">25.8%</td>
<td colspan="1" rowspan="1">26.1%</td>
<td colspan="1" rowspan="1">26.3%</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">25.5%</td>
<td colspan="1" rowspan="1">25.6%</td>
<td colspan="1" rowspan="1">25.6%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adj. Earnings per Share&#x2A;1</td>
<td colspan="1" rowspan="1">$0.70</td>
<td colspan="1" rowspan="1">$0.71</td>
<td colspan="1" rowspan="1">$0.72</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$2.65</td>
<td colspan="1" rowspan="1">$2.66</td>
<td colspan="1" rowspan="1">$2.67</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Free Cash Flow1</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$890M</td>
<td colspan="1" rowspan="1">$920M</td>
<td colspan="1" rowspan="1">$940M</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
</tbody>
</table>
</figure>
 &nbsp;

Howmet Aerospace Updates FY24 Guidance: Now Sees Revenue Of $7.39B-$7.43B (Prior $7.40B-$7.48B) vs $7.446B Est.; Adj. EPS Of $2.65-$2.67 (Prior $2.53-$2.57) vs $2.59 Est.

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Aquestive Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AQST#NASDAQ">AQST</a>) with a Buy and maintains $10 price target.

AQST

HC Wainwright & Co. Reiterates Buy on Aquestive Therapeutics, Maintains $10 Price Target

Immunocore Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMCR#NASDAQ">IMCR</a>) reported quarterly earnings of $0.17 per share which beat the analyst consensus estimate of $(0.35) by 148.57 percent. This is a 750 percent increase over earnings of $0.02 per share from the same period last year. The company reported quarterly sales of $80.25 million which missed the analyst consensus estimate of $80.60 million by 0.43 percent. This is a 23.74 percent increase over sales of $64.85 million the same period last year.

IMCR

Immunocore Hldgs Q3 2024 GAAP EPS $0.17 May Not Be Comparable To $(0.35) Estimate, Sales $80.25M Miss $80.60M Estimate

JP Morgan analyst Dan Walk downgrades Aris Water Solutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARIS#NYSE">ARIS</a>) from Overweight to Neutral and raises the price target from $19 to $22.

ARIS

JP Morgan Downgrades Aris Water Solutions to Neutral, Raises Price Target to $22

B of A Securities analyst Tazeen Ahmad maintains Apellis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) with a Buy and lowers the price target from $61 to $47.

APLS

B of A Securities Maintains Buy on Apellis Pharmaceuticals, Lowers Price Target to $47

The ODP Corporation today announced a partnership with a large, growing strategic reseller organization, offering quality office, furniture, print, promotional and facility resource solutions to large multi-site companies. This partnership, worth up to $1.5 billion spanning a 10-year period, will leverage the reseller provider's expertise in creating custom, results-driven e-commerce solutions and the Company's extensive fulfillment centers and delivery network.
"This collaboration enables a leader in reseller services to leverage our comprehensive product and service offerings, national distribution and award-winning e-commerce platform to service their customers," said David Centrella, EVP of The ODP Corporation and President of ODP Business Solutions. "This partnership reflects our commitment to providing solutions that address unique business needs."

ODP Announced 10-Year $1.5B Partnership With Nationally Recognized Strategic Reseller Organization Offering Quality Office, Furniture,

Royalty Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPRX#NASDAQ">RPRX</a>) reported quarterly sales of $565.00 million which missed the analyst consensus estimate of $696.10 million by 18.83 percent. This is a 5.41 percent increase over sales of $536.00 million the same period last year.

Earnings Misses

Royalty Pharma Q3 Sales $565.00M May Not Be Comparable To $696.10M Estimate

ALX Oncology Holdings ( ($ALXO) ) has shared an update. Sophia Randolph, the Chief Medical Officer of ALX Oncology Holdings Inc., has announced her...

ALX Oncology CMO Sophia Randolph Announces Resignation

Warning: ALXO is at high risk of performing badly

ALXO

Press Releases

ALX Oncology Announces Participation in the Jefferies Global Healthcare Conference

ALX Oncology Presents First Evorpacept Combination Data with an Antibody-Drug Conjugate from Phase 1 ASPEN-07 Clinical Trial in Patients with Advanced Bladder Cancer

Health Care

ALX Oncology to Host Investor Call and Webcast to Share Topline Data Results From ASPEN-06 Phase 2 Clinical Trial of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer

ALX Oncology Reports Topline Data From ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Improves Tumor Response in Patients With HER2-Positive Gastric Cancer

Management

ALX Oncology Appoints Alan Sandler, M.D., to Board of Directors

ALX Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update

ALX Oncology Announces First Patients Dosed with Evorpacept and Sarclisa As Part of Randomized Phase 1/2 UMBRELLA Study with Sanofi

ALX Oncology to Present at the 2024 Cantor Fitzgerald Global Healthcare Conference

ALX Oncology Announces Results from Phase 1b/2 Trial of Evorpacept in Combination with Zanidatamab will be Presented at the San Antonio Breast Cancer Symposium (SABCS) 2024

Comments

ALX Oncology Holdings

Notizie

Ultime notizie per ALX Oncology Holdings (NASDAQ:ALXO) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO